The Yankees and Blue Jays could wind up circling the same name as the deadline approaches, and that name is Luis Arraez.
For New York, the logic is simple: if there’s a chance to upgrade the offense, the Yankees should be willing to sort out the defensive pieces later. The source material makes the case that the real separator for this club in October will be what it does at the plate, assuming the pitching staff holds up. Defense still matters, of course, but the idea here is that the Yankees can afford to shuffle players around if it helps them score more.
Toronto fits into that conversation too. The Blue Jays have been one of the more intriguing teams to watch at this year’s deadline, and their uneven season could make it easier for the Yankees to land quality help if both clubs are chasing the same player.
Arraez has been floated as an option for both teams, and he’d give either lineup a boost. Chris Landers wrote, “Also as good as gone: Arraez, one of the sole bright spots for the Giants this year who is set to become a free agent at season's end. There's always the chance that his resurgence at second base collapses away from the tutelage of Ron Washington, but as it stands, he's been a very good two-way player this year at an awfully thin position,”
That’s the appeal. Arraez has at times looked like the best second baseman potentially available this season, and even with questions about whether the defense holds, his offensive value is hard to ignore. He puts the ball in play, and that alone makes him an attractive deadline target for either the Yankees or the Blue Jays.
In Other News...
Yankees Just Got Linked To A Trade Fans Will Hate Or Love
A speculative trade idea from Bleacher Report has the Yankees in an eye-catching spot, with the discussion centered on whether a utility infielder could be worth parting with a pair of pitching prospects. The appeal on New Yorks side is easy to see: Carlos Lagrange brings big arm strength and starter upside, while Eric Reyzelman has also drawn enough attention to be included in the kind of package that gets people talking.
Lagrange, in particular, has the sort of profile that makes these proposals divisive. The 23-year-old right-hander can reach 100 mph, pairs that heater with an above-average slider, and was effective in Triple-A before a shoulder injury complicated his season. On the other side of the idea sits Zack Gelof, a versatile infielder with years of team control and an .823 OPS, which is exactly why this kind of rumor can split a fan base right down the middle. [Read more 🡒]
Aaron Boone Finally Addressed The Anthony Volpe Confusion
The Yankees shortstop conversation has been noisy enough that it started to feel bigger than the actual depth chart, with Jose Caballeros name entering the debate and Anthony Volpe suddenly having to answer for a position he has long owned. Aaron Boone stepped in to calm some of that down, making clear that Volpe remains the clubs shortstop and treating him like the incumbent rather than a player fighting to keep a job.
Boones comments also helped separate the real baseball question from the rumor mill surrounding Volpes role. The Yankees have supported him as the starter, and while the chatter around a possible move has lingered, the team has not asked him to play elsewhere, leaving the focus where it belongs: on how the Yankees sort out the infield behind the guy they still view as their shortstop. [Read more 🡒]
A Forgotten Yankees Prospect From 2016 Is Back For The Worst Reason
A former Yankees pitching prospect from the 2016 system has resurfaced in an unwelcome way, this time in the Rockies Triple-A orbit. At 34, he is still hanging around professional baseball after a career that never quite matched the early buzz, one that took him out of the Yankees pipeline and eventually led to a major league debut with Oakland.
What makes the latest turn notable is less the uniform than the reason for it. The right-handers path has already included the usual grind of a fluctuating career, but now he is back in the news for a suspension tied to performance-enhancing drugs, a reminder that even players long removed from the spotlight can still leave one more awkward footnote behind. [Read more 🡒]